中度至重度炎症性肠病患者的最佳管理
1Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University Texas McGovern Medical School, Houston, TX 77030, USA.
Journal of clinical medicine
|December 17, 2024
概括
本综述涵盖了炎症性肠病 (IBD) 治疗的演变,从早期疗法到现代生物药物和口服药物. 它指导临床医生进行个性化,以患者为中心的IBD管理,以实现最佳的疾病控制.
科学领域:
- 胃肠道学和免疫学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),是一种具有复杂管理需求的慢性疾病.
- 了解IBD病理生理学在过去几十年中推动了治疗策略的重大进展.
研究的目的:
- 为IBD治疗的演变提供全面的概述.
- 讨论当前的治疗目标,包括临床缓解,粘膜愈合和生活质量.
- 为临床医生提供IBD先进疗法的个性化和早期使用的指导.
主要方法:
- 关于IBD治疗演变的文献综述.
- 对当前FDA批准的生物和小分子药物的分析 (2024年).
- 讨论新兴的口腔疗法和未来的治疗方向.
主要成果:
- 治疗方法已经从症状管理转向向治疗.
- 生物药物和新型口服药物为中度至重度IBD提供了更好的疗效.
- 个性化和早期治疗策略对于最佳结果至关重要.
结论:
- 肠胃炎症治疗的格局发生了变化,提供了更有效和更有针对性的选择.
- 个性化医疗和以患者为中心的决策是管理IBD的关键.
- 正在进行的新疗法研究有望进一步改善IBD护理.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
315
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
315
Inflammatory Bowel Disease V: Surgical Management
116
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
116
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119


